BR112017010592A2 - análogos de ureia ligados em ponte substituídos como moduladores de sirtuína - Google Patents

análogos de ureia ligados em ponte substituídos como moduladores de sirtuína

Info

Publication number
BR112017010592A2
BR112017010592A2 BR112017010592A BR112017010592A BR112017010592A2 BR 112017010592 A2 BR112017010592 A2 BR 112017010592A2 BR 112017010592 A BR112017010592 A BR 112017010592A BR 112017010592 A BR112017010592 A BR 112017010592A BR 112017010592 A2 BR112017010592 A2 BR 112017010592A2
Authority
BR
Brazil
Prior art keywords
disorders
diseases
sirtuin
present
substituted bridged
Prior art date
Application number
BR112017010592A
Other languages
English (en)
Inventor
H White Brian
G Szczepankiewicz Bruce
A Blum Charles
Oalmann Christopher
S Disch Jeremy
Koppetsch Karsten
Yee Ng Pui
Casaubon Rebecca
Dana Caldwell Richard
B Perni Robert
Michael Fox Ryan
Henry Miller William
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Priority claimed from PCT/US2015/061501 external-priority patent/WO2016081692A2/en
Publication of BR112017010592A2 publication Critical patent/BR112017010592A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

resumo ?análogos de ureia ligados em ponte substituídos como moduladores de sirtuína? a presente invenção se refere a novos compostos de ureia ligados em ponte substituídos, análogos relacionado correspondentes, composições farmacêuticas e métodos de uso dos mesmos. compostos moduladores de sirtuína da presente invenção podem ser usados para aumentar a expectativa de vida de uma célula e tratar e/ou prevenir uma ampla variedade de doenças e transtornos, que incluem, mas não são limitados, por exemplo, às doenças ou transtornos relacionados ao envelhecimento ou estresse, diabetes, obesidade, doenças neurodegenerativas, doença cardiovascular, transtornos de coagulação sanguínea, inflamação, câncer, e/ou eritema, assim como doenças ou transtornos que se beneficiariam de atividade mitocondrial aumentada. a presente invenção também está relacionada às composições compreendendo um composto modulador de sirtuína em combinação com um outro agente terapêutico.
BR112017010592A 2013-05-13 2015-11-19 análogos de ureia ligados em ponte substituídos como moduladores de sirtuína BR112017010592A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361822758P 2013-05-13 2013-05-13
PCT/US2014/037767 WO2014186313A1 (en) 2013-05-13 2014-05-13 Substituted bridged urea analogs as sirtuin modulators
US14/547,861 US9834558B2 (en) 2013-05-13 2014-11-19 Substituted bridged urea analogs as sirtuin modulators
PCT/US2015/061501 WO2016081692A2 (en) 2014-11-19 2015-11-19 Substituted bridged urea analogs as sirtuin modulators

Publications (1)

Publication Number Publication Date
BR112017010592A2 true BR112017010592A2 (pt) 2018-03-06

Family

ID=53264426

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112015028613A BR112015028613A2 (pt) 2013-05-13 2014-05-13 análogos de uréia com ligações por pontes substituída como moduladores de sirtuína
BR112017010592A BR112017010592A2 (pt) 2013-05-13 2015-11-19 análogos de ureia ligados em ponte substituídos como moduladores de sirtuína

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112015028613A BR112015028613A2 (pt) 2013-05-13 2014-05-13 análogos de uréia com ligações por pontes substituída como moduladores de sirtuína

Country Status (11)

Country Link
US (4) US9765075B2 (pt)
EP (2) EP2997029B1 (pt)
JP (2) JP6376707B2 (pt)
KR (2) KR20160006215A (pt)
CN (2) CN105392788B (pt)
AU (3) AU2014265671B2 (pt)
BR (2) BR112015028613A2 (pt)
CA (2) CA2912683A1 (pt)
ES (1) ES2718550T3 (pt)
RU (2) RU2015153061A (pt)
WO (1) WO2014186313A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9624184B2 (en) * 2013-04-04 2017-04-18 Takeda Pharmaceutical Company Limited Heterocyclic compound
KR20160006215A (ko) * 2013-05-13 2016-01-18 글락소스미스클라인 엘엘씨 시르투인 조절제로서의 치환된 가교 우레아 유사체
JP2016079173A (ja) * 2014-10-15 2016-05-16 日本合成化学工業株式会社 新規ピリジン系化合物、それを用いたアニオン硬化性化合物用硬化剤、硬化性組成物及び硬化物
BR112017010601A2 (pt) * 2014-11-19 2017-12-26 Glaxosmithkline Ip No 2 Ltd análogos de ureia substituídos em ponte como moduladores de sirtuínas
WO2016095089A1 (en) * 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Erk inhibitors
WO2016095088A1 (en) 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Erk inhibitors
US10364245B2 (en) 2017-06-07 2019-07-30 Chiesi Farmaceutici S.P.A. Kinase inhibitors
WO2019040404A1 (en) * 2017-08-21 2019-02-28 Microbiotix, Inc. METABOLIC-STABLE METABOLIC-N-ACYLAMINOOXADIAZOLES USEFUL AS ANTIBACTERIAL AGENTS
JP7156207B2 (ja) * 2019-08-07 2022-10-19 株式会社島津製作所 糖ペプチド解析装置
CN112759593A (zh) * 2019-11-01 2021-05-07 北京伯汇生物技术有限公司 桥环并醛基吡啶衍生物及其应用
CN112094362B (zh) * 2020-09-29 2022-04-12 四川大学华西医院 烟酰胺核糖或单核苷酸类似物-大分子载体轭合物及制法和应用
CN112645805A (zh) * 2020-12-23 2021-04-13 北京理工大学 一种由温勒伯酰胺制备均苯三甲醛的方法
CN115518062B (zh) * 2022-09-02 2024-03-22 成都大学 Phellopterin在制备用于治疗STAT信号通路介导的相关疾病药物中的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DE4424484A1 (de) * 1994-07-12 1996-01-18 Bayer Ag Azofarbstoffe, deren Herstellung und Verwendung
AU2005263577C1 (en) * 2004-07-16 2010-08-26 Proteosys Ag Muscarinic antagonists with PARP and SiR modulating activity as cytoprotective agents
CA2595159A1 (en) * 2005-01-13 2006-07-20 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
WO2006094248A1 (en) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Aryl-substituted cyclic sirtuin modulators
WO2006094210A2 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Tetrahydroquinoxalinone sirtuin modulators
US20060229265A1 (en) 2005-03-30 2006-10-12 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
JP5506386B2 (ja) * 2006-09-04 2014-05-28 ユニバーシティー・コート・オブ・ザ・ユニバーシティー・オブ・ダンディー Ｐ５３活性化化合物
AU2008339572B2 (en) 2007-12-21 2012-05-10 Astrazeneca Ab Bicyclic derivatives for use in the treatment of androgen receptor associated conditions
MX2010012010A (es) 2008-05-01 2010-11-30 Sirtris Pharmaceuticals Inc Quinolinas y analogos relacionados como moduladores de sirtuin.
CA2738809C (en) 2008-09-29 2015-11-24 Sirtris Pharmaceuticals, Inc. Quinazolinone, quinolone and related analogs as sirtuin modulators
BRPI0919625A2 (pt) * 2008-10-29 2015-12-01 Sirtris Pharmaceutical Inc piriridina, piridina bicíclica e análogos relacionados como moduladores de sirtuína
NZ594122A (en) 2008-12-19 2013-03-28 Sirtris Pharmaceuticals Inc 2-Phenyl-N-(2-(6-(pyrrolidin-1-ylmethyl)thiazolo[5,4-b]pyridin-2-yl)phenyl)thiazole-4-carboxamide derivatives
WO2011059839A1 (en) * 2009-10-29 2011-05-19 Sirtris Pharmaceuticals, Inc. Bicyclic pyridines and analogs as sirtuin modulators
AU2012325916A1 (en) 2011-10-20 2014-05-01 Glaxosmithkline Llc Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
KR20160006215A (ko) 2013-05-13 2016-01-18 글락소스미스클라인 엘엘씨 시르투인 조절제로서의 치환된 가교 우레아 유사체
WO2016081692A2 (en) 2014-11-19 2016-05-26 Glaxosmithkline Llc Substituted bridged urea analogs as sirtuin modulators

Also Published As

Publication number Publication date
CN107207496A (zh) 2017-09-26
CN105392788B (zh) 2018-10-23
JP2017536364A (ja) 2017-12-07
JP6376707B2 (ja) 2018-08-22
EP2997029A4 (en) 2017-05-24
WO2014186313A8 (en) 2015-12-23
JP2016518448A (ja) 2016-06-23
US20160083386A1 (en) 2016-03-24
US20180044338A1 (en) 2018-02-15
CA2975291A1 (en) 2016-05-26
WO2014186313A1 (en) 2014-11-20
ES2718550T3 (es) 2019-07-02
CA2912683A1 (en) 2014-11-20
RU2015153061A3 (pt) 2018-03-21
EP2997029B1 (en) 2019-01-09
BR112015028613A2 (pt) 2017-07-25
EP3221312A4 (en) 2018-05-30
RU2015153061A (ru) 2017-06-15
RU2017120859A (ru) 2018-12-20
US9765075B2 (en) 2017-09-19
AU2017204176A1 (en) 2017-07-13
AU2017204176B2 (en) 2018-07-26
AU2015349912A1 (en) 2017-06-01
US20170355697A1 (en) 2017-12-14
AU2014265671A8 (en) 2016-06-16
US10590135B2 (en) 2020-03-17
US9834558B2 (en) 2017-12-05
EP2997029A1 (en) 2016-03-23
AU2014265671A1 (en) 2015-11-26
US20150152108A1 (en) 2015-06-04
KR20170084274A (ko) 2017-07-19
CN105392788A (zh) 2016-03-09
AU2014265671B2 (en) 2017-04-06
JP6833686B2 (ja) 2021-02-24
KR20160006215A (ko) 2016-01-18
EP3221312A2 (en) 2017-09-27

Similar Documents

Publication Publication Date Title
BR112017010592A2 (pt) análogos de ureia ligados em ponte substituídos como moduladores de sirtuína
BR112012010010A2 (pt) piridinas bicíclicas e análogos como moduladores da sirtuína
CR20110353A (es) Compuestos de tiazolopiridina moduladores de sirtuina referencia cruzada
BR112017010602A2 (pt) análogos de ureia ligados em ponte substituídos como moduladores de sirtuína
GT201400034A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
EA201170137A1 (ru) Бензимидазолы и родственные аналоги в качестве модуляторов сиртуина
UY31170A1 (es) Compuestos moduladores de sirtuina
EP2342188A4 (en) CHROMENONE ANALOGUES AS MODULATORS OF SIRTUIN
MX2010012961A (es) Imidazopiridina y analogos relacionados como moduladores de sirtuina.
MX2011006475A (es) Ftalazinona y analogos relacionados como moduladores de sirtuina.
MX2011009213A (es) Quinolinas 8-sustituidas y analogos relacionados como moduladores de sirtuina.
EA201071263A1 (ru) Хинолины и их аналоги в качестве модуляторов сиртуина
UY31169A1 (es) Compuestos moduladores de sirtuinas
MX2011006084A (es) Isoindolinona y analogos relacionados como moduladores de sirtuina.
CL2019002671A1 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1.
EA201070551A1 (ru) Сиртуинмодулирующие соединения
EA201070579A1 (ru) Солюбилизированные тиазолопиридины
FI20115135A0 (fi) Mikrofibrilloidun selluloosan tulehduksia estävä vaikutus
BR112015017251A8 (pt) composições farmacêuticas compreendendo doadores de nitroxil, misturas e usos das referidas composições farmacêuticas
BR112017012588A2 (pt) compostos heteroaril-heteroarila bicíclicos de ácido benzoico como agonistas de receptores beta do ácido retinoico (rarbeta)
UY38986A (es) Compuestos derivados de 3-(5-metoxi-1-oxoisoindolin-2-il) piperidin-2,6-diona, métodos de usos de los mismos y combinaciones farmacéuticas
CL2012000013A1 (es) Compuestos derivados de 4-{3-[3-(4-trifluorometil-fenil)ureido]-5-fluoro-bencilamino}-1h-pirazol-3-carboxamida; procedimiento de preparacion; composicion farmaceutica que los comprende; compuestos intermediarios; y su uso como moduladores de la actividad de las proteinas quinasa para el tratamiento del cancer.
BR112015022290A2 (pt) derivados de heterocíclicos benzo-fundidos úteis como agonistas de gpr120
EA201492154A1 (ru) Косметическая и/или фармацевтическая композиция для лечения воспаления кожи и связанных синдромов
WO2016081692A3 (en) Substituted bridged urea analogs as sirtuin modulators

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]